Efficacy models for specialised indications

Beyond major therapeutic areas, many innovative programmes target complex, niche or organ‑specific indications requiring highly specialised preclinical models. These indications often combine structural damage, immune dysregulation, tissue remodelling or acute pathological events, making standard models insufficient to generate meaningful pharmacodynamic data.

At CER Groupe, we support these programmes through customised preclinical efficacy and pharmacodynamic studies, leveraging our research centre + CRO model to design, adapt or co‑develop disease‑relevant models. This hub page presents a selection of specialised domains where CER Groupe provides robust, translational support.

Bone & skeletal disorders

Scope & applications

Bone‑related programmes often focus on regeneration, repair, infection or structural integrity, requiring precise control of defect size, location and mechanical environment.

In vivo efficacy models

Critical and sub‑critical size bone defect models
Osteochondral defect models
Ovariectomy (OVX)‑induced bone loss models (osteoporosis‑related)
Bone infection models (including osteomyelitis)

Key readouts

µCT‑based structural analysis, histology and histomorphometry, biomaterial integration, inflammatory and remodelling biomarkers.

Plan your study

Pulmonary & respiratory diseases

Scope & applications

Pulmonary indications involve acute or chronic inflammation, tissue remodelling and impaired respiratory function, often requiring integrated functional and pathological assessment.

In vivo efficacy models

LPS‑induced lung inflammation
Pulmonary fibrosis‑associated inflammation models
Asthma‑ and COPD‑like inflammatory settings (where relevant)

Key readouts

Inflammatory cell infiltration, cytokine profiling, histopathology, lung structure and functional endpoints (study‑dependent).

Liver diseases

Scope & applications

Liver diseases are characterised by metabolic stress, inflammation, fibrosis and progressive tissue damage, requiring models that capture both systemic and organ‑specific effects.

In vivo efficacy models

NAFLD / NASH‑like models
Liver fibrosis models (chemical‑induced)
Acute liver injury models (e.g. drug‑induced)

Key readouts

Serum biomarkers (ALT, AST, ALP), lipid and metabolic parameters, histopathology (steatosis, inflammation, fibrosis), molecular biomarkers.

GVHD & immune‑mediated complications

Scope & applications

Graft‑versus‑host disease (GVHD) and related immune complications require immune‑driven models capturing systemic and tissue‑specific immune damage.

In vivo efficacy models

Acute and chronic GVHD models
Immune‑mediated tissue injury settings

Key readouts

Survival, clinical scoring, immune‑cell profiling, cytokine panels, tissue histopathology.

Start Your Project

Wound healing & tissue repair

Scope & applications

Wound healing programmes focus on tissue regeneration, angiogenesis and inflammation resolution, often in compromised settings.

In vivo efficacy models

Excisional wound healing models
Delayed or impaired wound healing models (e.g. metabolic context)
Biomaterial‑assisted repair settings

Key readouts

Wound closure kinetics, digital imaging, histology (re‑epithelialisation, angiogenesis), inflammatory and regenerative biomarkers.

Thrombolysis & acute vascular events

Scope & applications

Thrombolytic strategies target acute vascular occlusion, requiring short‑term, highly controlled models.

In vivo efficacy models

Catheter‑induced thrombus models
Acute thrombosis and clot‑resolution settings

Key readouts

Clot dissolution, vascular patency, haemodynamic parameters, safety‑related endpoints.

Supporting in vitro & cell‑based assays

Across these specialised domains, in vivo studies can be complemented by targeted in vitro and cell‑based assays, including:

Cell characterisation and phenotyping (flow cytometry, ICC/IF)
Inflammatory and immune‑modulation assays (MSD multiplex, ELISA, qPCR)
Cytotoxicity and biocompatibility profiling (MTT, LDH, apoptosis/necrosis)
Functional assays (migration, secretion profiling)

These assays support mechanism validation, candidate ranking and biomarker selection.

Custom model development for niche indications

Many specialised indications require bespoke preclinical approaches. CER Groupe offers:

Adaptation of existing models to specific pathophysiology
Co‑development of new or hybrid models
Integration of novel biomarkers and functional readouts
Pilot feasibility and validation studies

This flexibility is a key differentiator for first‑in‑class therapies and innovative medical devices.

Why choose CER Groupe for specialised domains?

Research centre + CRO, enabling rapid model adaptation
Strong expertise in complex and niche indications
Integrated in vivo, in vitro, imaging and biomarker platforms
GLP-like data integrity supporting downstream development
Experience across pharma, biotech and medtech programmes

Partner With Us